Executive Briefing presented by the Center for Anti-Infective Agents (CEFAIA)

Mark your calendar as the dates have been set for the 3rd Antibacterial Market Executive Briefing. Join us on November 1st, 14:00 to 18:00, in Vienna, Austria.

Challenges in the antibacterial market
Moving out of survival mode

Information and registration

On behalf of ISAP Ursula Theuretzbacher has organized the Post-ICAAC symposium in San Francisco

Ursula Theuretzbacher has been invited to participate in the Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), SAn Francisco 2009, USA

Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

The review about the future of antibiotics has been published:

Ursula Theuretzbacher: Future antibiotics scenarios: is the tide starting to turn?
International Journal of Antimicrobial Agents: Volume 34, Issue 1, Pages 15-20

Ursula Theuretzbacher will present at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

16-19th May 2009, Helsinki, Finnland

Educational workshop:
Pharmacokinetics and pharmacodynamics of anti-infective agents.

U. Theuretzbacher has been invited to present at the

6th Anti-Infectives Partnering & Deal-Making Summit
March 5-6, 2009, Boston, MA

Diagnostics Team Up with Narrow-Spectrum Antibiotics: Synergistic Business Opportunities and Evolving Trends

The development of narrow-spectrum or single pathogen–only antibiotics is increasingly seen as attractive niche market opportunities. Resistance challenges, antibiotic control programs in hospitals, escalating health care costs, long development time lines, regulatory environment challenges, and dry pipelines, power the trend to more targeted therapies. Driven by the principles of personalized medicine, the hospital point-of care rapid diagnostic market promises dramatic market expansion via improved and rapid tests that are reliable and easy to integrate into hospital routine. Diagnostic-therapeutic co-development and early partnerships will be important drivers for targeting the clinical trial population and accessing markets more rapidly and efficiently. This overview discusses
• Existing examples for diagnostic-therapeutic partnerships
• Strategies for the clinical development phase
• Regulatory opportunities and pitfalls
• Synergistic strategies for diagnostic and drug development companies in the market

U. Theuretzbacher has been invited to present at the

Re-emerging Infectious Diseases conference
11th -12th December 2008, London UK

Cultural implications for antibacterial drug development and usage
• Differences in general perception of medicine and antibiotic usage in US vs EU
• Medical need – everywhere the same?
• Cultural implications regarding drug development and commercialization strategies in US vs EU

U. Theuretzbacher has been invited to participate in the Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington D.C. 2008, USA

Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Mark your calendar as the dates have been set for the Executive Briefing November 16th, 14:00 to 18:00 in Mannheim, Germany

Optimising partnering strategies in the anti-infectives market
The comeback of the antibacterial business

Information and registration

U. Theuretzbacher has been invited to present at the

2nd World Conference on Magic Bullets (Ehrlich II) in Nürnberg, Germany, October 3 - 5, 2008

Oral presentation:
Evaluating our performance: Tissue penetration paradigm shift
Abstract

PK/PD workshop

The leading article about tissue concentrations has been published:

Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O: Tissue concentrations: do we ever learn?
J Antimicrob Chemother. 2008;61(2):235-7

Ursula Theuretzbacher will present at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID):

• Educational workshop:
  Pharmacokinetics and pharmacodynamics of anti-infective agents. Handout
• Meet-the-Expert session:
  What is the role of PK/PD in the management of fungal infections? How to handle in the everyday life?
• Symposium:
  Antibiotic stewardship in the ICU: today and tomorrow

The review about PK/PD has been published:

Ursula Theuretzbacher: Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Current Opinion in Pharmacology 2007, 7:498–504

U. Theuretzbacher has been invited to present at 11th International Symposium
"Current Topics in Infectious Diseases"
January 27 - February 1, 2008

Antibiotics: what’s new and what’s in the pipeline?

U. Theuretzbacher has been invited to present at FDA in Washington DC, Division of Pharmaceutical Evaluation III, Oct 22nd, 2007

The Influence of Tissue Distribution and Protein Binding on Resistance.

Abstract

U. Theuretzbacher has been invited to participate in the APUA 2nd world congress in Boston, Oct 29-30th, 2007

Symposium "Future Strategies in Drug Development and Prescribing"

Robert C. Moellering, MD, Beth Israel Deaconess Medical Center, Harvard Medical School — “New concepts of anti-infective therapy” — Tentative
• Ian Gould, PhD, MBChB, FRCPE, FRCPath , Consultant Microbiologist, Aberdeen Royal Infirmary, UK — “Unintended consequences of prescribing
policies”
• Dominique L. Monnet, PharmD, PhD, Statens Serum Institut, Denmark — “Encouraging development of new antibacterials while preserving the old”
• Ursula Theuretzbacher, PhD, Center for Anti-Infective Agents — “Antimicrobials in the future”
• Steven J. Projean, PhD, Biological Technologies, Wyeth Research — “How can we control antibiotic resistance when we don’t understand it?”

U. Theuretzbacher has been invited to run the Executive Briefing following the smi-conference Superbugs & Superdrugs in London, 23rd to 24th April 2007

This Executive Briefing will explore the biggest issues in antibacterial resistance looking in-depth at the current market and forward 10 years into the future. Attendees will explore the resistance problem and examine the current R&D pipeline.

Report: Resisting the call for new antibacterials?

U. Theuretzbacher has been invited to present at the 4th Anti-Infectives Partnering & Deal-Making Summit - Jan. 25-26, 2007, San Francisco, USA

U. Theuretzbacher has been invited to participate in the ISC working session: Reconciling the goals of antibiotic policy and drug development.
17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy (ICC), Munich/Germany, 31 March - 3 April 2007
Symposium, jointly organised by the ISC Working Group on Future Antimicrobials and the ESCMID Study Group on Antibiotic Policies

Conveners: Jean Claude Pechère, Geneva, CH
Inge C. Gyssens, Rotterdam, NL

Topics:
Antimicrobials in the future
New concepts of anti-infective therapy
Optimal strategies for use of new antimicrobials
Panel discussion

Faculty: Ursula Theuretzbacher, Vienna, AT
Robert C. Moellering, Boston, US
Dominique L. Monnet, Copenhagen, DK
Michael M. Dudley, San Diego, US
William A. Craig, Madison, US
Ian Gould, Aberdeen, UK

U. Theuretzbacher has been invited to present at the 8th European Conference of Chemotherapy in Budapest, Oct 25-28, 2006

Abstract

The review about the pharmacokinetics and pharmacodynamics of voriconazole has been published:

U. Theuretzbacher, F. Ihle, H. Derendorf: Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. Clin Pharmacokinet 2006; 45 (7): 649-663

Abstract

U. Theuretzbacher is chairing the working group of the International Society of Chemotherapy (ISC): Antimicrobials of the Future

Some ideas

The review about the future of antibiotics has been published:

U. Theuretzbacher, J. Toney: Nature's clarion call of antibacterial resistance: are we listening? Curr Opin Investig Drugs. 2006 Feb;7(2):158-66.

Abstract

U. Theuretzbacher has been invited to present at the Annual Conference on Antimicrobial Resistance - June 26-28, Bethesda, USA

U. Theuretzbacher has been invited to participate in the Educational Workshop of ISAP (International Society of Anti-Infective Pharmacology) in cooperation with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice 2006, France

U. Theuretzbacher has been invited to present at the 3rd Anti-Infectives Partnering & Deal-Making Summit - Jan. 26-27, San Diego, USA

Abstract

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington 2005, USA

Introduction to PK/PD
H. Derendorf, PhD
Department of Pharmaceutics, University of Florida, Gainsville, FL

PK/PD indices
J. Mouton, MD, PhD
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

Protein binding, tissue distribution
U. Theuretzbacher
Center for Anti-Infective Agents, Vienna, Austria

In vitro models
I. Odenholt, MD
Departement of Infectious Diseases, Malmö University Hospital, Malmö, Sweden

Animal models
W.A. Craig,
Division of Infectious Diseases, University of Wisconsin, Madison, WI

In vitro resistance
O. Cars,
Division of Infectious Diseases, University Hospital, Uppsala, Sweden

U. Theuretzbacher has been invited to participate in the symposium Clinical Issues of PK/PD organized by the
European Congress of Chemotherapy and Infection (ECC), Florence, Italy

Abstract

Clinical Issues of PK/PD
Chairmen: W.A. Craig (USA) - F. Scaglione (Italy)
Thursday, October 20th 2005, 14.30 - 16.00
• PK/PD in special populations (H. Derendorf, USA)
• Clinical implications of tissue concentrations (U. Theuretzbacher, Austria)
• Clinical implications and recommendations based on PK/PD relationships (J.W. Mouton, The Netherlands)
• Role of clinical pharmacologists in the PK/PD aera (G.L. Drusano)

The review about beta-lacatamases has been published:

U. Theuretzbacher: Beta-Lactamases and Beta-Lactamase Inhibitors - an update. Chemotherapie-Journal 2004 (13) 5

The review about PK/PD of Echinocandins has been published online:

U. Theuretzbacher: Pharmacokinetics/Phamacodynamics of Echinocandins. European Journal of Clinical Microbiology and Infectious Diseases 2004, published online: 14 October 2004

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington 2004, USA

World Conference on Dosing of Antiinfectives, Nürnberg, Germany
Program: Introduction to PK/PD (Derendorf)
PK/PD indices (Mouton)
Protein Binding/Tissue Distribution (Theuretzbacher)
In vitro models (Mouton)
Animal models (Craig)
In vitro resistance (Cars)

The second edition of the textbook "U. Theuretzbacher: Mikrobiologie im klinischen Alltag (Microbiology for primary care physicians and specialists) has been published and is available now. It has 800 pages and deals with all aspects of pathogens, diagnosing and treating with anti-infective agents. Doctors love it and I am getting great feed back.